We have a shared ambition to transform the lives of people living with severe diseases. We focus on central nervous system and immunology disorders – putting patients at the center of our world.

A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue to €5.5 billion in 2022.

• We combine biology and chemistry to make major breakthroughs.By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families living with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
• We partner with the leaders in the pharmaceutical industry.The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners - we play to our strengths and tap into the organisations with greater or complementary strengths.

Many companies claim to be patient-driven, but for UCB it is a living reality. In fact, we do not think of people with severe diseases as "patients" but as individuals with lives beyond their disease.